News Daily News Universal Risk Tool Works Well in Both Primary and Secondary Prevention Michael O'Riordan February 01, 2024
News Daily News FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions Todd Neale January 12, 2024
News Daily News Counting Quality, Not Carbs, May Be Key to Weight Management L.A. McKeown January 05, 2024
News Daily News Top General Cardiology and CVD Prevention News of 2023 Yael L. Maxwell January 03, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2023 Caitlin E. Cox December 28, 2023
News Daily News Who Benefits Most From Semaglutide and How Long Will That Take? Shelley Wood December 19, 2023
News Daily News Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk Todd Neale December 12, 2023
News Daily News Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose L.A. McKeown December 01, 2023
Presentation Controversies and Advances 2023 Obesity and Cardiovascular Disease Presenter: Steven E. Nissen November 30, 2023
News Daily News ‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults Michael O'Riordan November 21, 2023
News Daily News Mortality Risk Varies Among Patients With Very High LDL Levels Michael O'Riordan November 17, 2023
News Conference News AHA 2023 Simultaneous Dual Cardioversion of AF Lessens Failure Rates in Obese Patients Todd Neale November 14, 2023
News Conference News AHA 2023 New CVD Risk Tool Can Spur Even Earlier Talk About Prevention Yael L. Maxwell November 14, 2023
News Conference News AHA 2023 Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics Todd Neale November 11, 2023
Presentation AHA 2023 Population Health and Obesity: Achieving Equity and Feasibility Presenter: Tiffany M. Powell-Wiley November 11, 2023
News Daily News FDA Grants Tirzepatide a New Indication for Obesity Management L.A. McKeown November 08, 2023
News Conference News HFSA 2023 Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis Todd Neale October 11, 2023